EHA 2023 | Performance of the AIPSS-MDS ML model in predicting OS & leukemic transformation in CMML
Adrian Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, comments on a study evaluating the performance of the Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS) developed to risk stratify myelodysplastic syndromes (MDS) in predicting overall survival (OS) and leukemic transformation in patients with chronic myelomonocytic leukemia (CMML). This model, which does not incorporate next-generation sequencing (NGS) data, was shown to outperform the accuracy of other well-established prognostic scores including the CMML-specific prognostic scoring system (CPSS) and the CPSS-Molecular (CPSS-Mol). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Roche, Amgen, AstraZeneca, Janssen, Abbvie, Takeda, Brystol, GSK, Pfizer,: Consultancy, Honoraria, Research Funding.
